Can Last Week’s Winners Anglo American plc, Acacia Mining PLC & Hikma Pharmaceuticals PLC Keep Charging?

Royston Wild discusses the investment case for Anglo American plc (LON: AAL), Hikma Pharmaceuticals Plc (LON: HIK) & Acacia Mining PLC (LON: ACA).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m looking at the investment prospects of three recent FTSE risers.

Stop digging!

Shares in mining goliath Anglo American (LSE: AAL) have stabilised since the start of January thanks to a solid uptick in the iron ore price. Many investors are speculating that the bottom has finally been ploughed, while extra US dollar weakness and a cancellation of ‘short’ positions has also sent shares in Anglo American hurtling skywards during the past week.

I’m convinced this strength presents nothing more than a fresh selling opportunity, however. Sure, iron ore prices may have received a welcome uptick more recently. But with Chinese economic cooling still accelerating, and domestic steelmaking activity sinking as the construction sector struggles, I reckon Anglo American’s surge is likely to peter out.

The London business is aggressively downscaling its operations to mitigate a poor earnings outlook, from ramping up cost savings and capex reductions to slashing around 60% of its asset base. But while wise in the current climate of falling commodity values, massive project sales are likely to seriously constrain profits growth once supply/demand imbalances eventually improve.

A medical marvel

Medicines giant Hikma Pharmaceuticals (LSE: HIK) had cause for further cheer last week as its share price continued to ignite. To say that the healthcare play has been volatile in recent months would be something of a colossal understatement, and I believe further turbulence can be expected in the weeks ahead as market sentiment shakes.

But in the long term I believe Hikma will prove a lucrative stock selection as earnings appear on course to surge.

All has not been rosy in the garden in recent times as weak demand for its Generics products forced the business to cut its full-year profit expectations for last year. Still, investors should be hugely confident in Hikma’s accelerating progress across the Middle East and North Africa, regions where healthcare spend continues to head higher.

And acquisitions like that of US-based Roxane Laboratories for $2.65bn last year are also bolstering the firm’s already-hot product pipeline, not to mention turbocharging its exposure to other white-hot geographies and product areas. I fully expect sales to explode at Hikma in the years ahead.

Gold bounce set to last?

I’m not so bullish over the long-term prospects of gold producer Acacia Mining (LSE: ACA) however, thanks to the fragile outlook for metal prices in 2016 and potentially beyond.

Investor appetite for the so-called ‘hard currency’ has exploded in recent sessions, a combination of dollar erosion and bubbly safe-haven buying pushing metal values markedly higher. Indeed, gold was dealing just shy of $1,180 per ounce just this morning, its most expensive since October.

Still, steady dollar appreciation put paid to commodity prices in 2015, and I expect these pressures to materialise again in the coming months as currency devaluation across the globe propels the greenback. And further Fed rate hikes can’t be ruled out either, despite poor economic data more recently casting some doubts over the scale of monetary tightening this year.

When you also factor-in a backdrop of low global inflation, not to mention still-weak physical gold demand in Asia, I believe the revenues outlook at Acacia — despite the potential impact of steady production increases — remains on shaky footing.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »